MabEase was the clinical trial testing subcutaneous Rituximab in DLBCL (Lugtenburg, Haematologica, Nov 2017).This was a randomized open label of subcut vs IV Ritux in 2:1 randomization in frontline DLBCL tx CD20 and CHOP therapy with a primary endpoint of CR, secondary endpoints of PFS and OS. Injec...

Rituximab (Rituximab) was the landmark addition to treatment of B cell-Non Hodgkin Lymphoma in the late 1990s. It changed the treatment for B cell NHL. Rituximab is also used in many other off label indications (as for example ITP, TTP etc.). Recently two bio-similars were approved by US FDA: Truxi...